Medroxyprogesterone acetate and cancer cachexia: Interleukin-6 involvement

Breast Cancer

Volumn 7, Issue 2, 2000, Pages 130-135

  Yamashita, Jun Ichi ^a   Ogawa, Michio ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; Cachexia; IL 6; MPA

Indexed keywords

INTERLEUKIN 6; MEDROXYPROGESTERONE ACETATE;

BLOOD; CACHEXIA; DIET THERAPY; FEMALE; HUMAN; NEOPLASM; PHYSIOLOGY; REVIEW;

CACHEXIA; FEMALE; HUMANS; INTERLEUKIN-6; MEDROXYPROGESTERONE 17-ACETATE; NEOPLASMS;

EID: 0034564354     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967444     Document Type: Review

References (52)

1. Loprinzi CL, Ellison NM, Schaid D J, et al: Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 82:1127-1132, 1990. (Pubitemid 20213253)
2. Laszlo J: Physicians guide to cancer care complications. In: Laszlo J, Dekker M eds, Prevention and Management, Fundamentals of Cancer Management Ser, New York, pp48-52, 1986.
3. DeWys WD, Begg C, Lavin PT, et al: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 69:491-497, 1980. (Pubitemid 10018703)
4. Peutler B, Greenwald D, Hulmes JD, et al: Identity of tumor necrosis factor and the macrophages-secreted factor cachecfin. Nature 316:352-354, 1985.
5. Hirano T, Yasaukawa K, Harada H, et al: Complementary DNA for a novel interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature (Lond) 324:73-79, 1986.
6. Kishimoto T: The biology of interleukin 6. Blood 74:1-10, 1990.
7. Hirano T: Interleukin-6. In: Thomson A ed, The Cytokine Handbook, Academic Press Ltd, London, pp169-190, 1991.
8. Kurzrock R, Redman J, Cabanillas F, et al: Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res 53: 2118-2222, 1993.
9. Blay J, Negrier S, Combaret V, et al: Serum level of interleukin 6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res 52:3317-3322, 1992.
10. Burt ME, Gonschboth CM, Brennan MF: A controlled prospective randomized trial evaluating the metabolic effects of enteral and parenteral nutrition in the cancer patient. Cancer 49:1092-1105, 1982. (Pubitemid 12187807)
11. Brennan MF: Total parenteral nutrition in the cancer patient. N Engl J Med 305:375-382, 1981. (Pubitemid 11063753)
12. Clamon GH, Feld R, Evans WK, et al: Effect of ad-juvant central IV hyperalimentation on the survival and response to treatment of patients with small cell lung cancer; A randomized trial. Cancer Treat Rep 69: 167-177, 1985. (Pubitemid 15170450)
13. Klein S, Simes J, Blockburn G: Total parenteral nutrition and cancer clinical trails. Cancer 58:1378-1386, 1986. (Pubitemid 16053158)
14. Nixon DW: The value of parenteral nutritional support. Cancer 58, 1902-1903, 1986.
15. Chlebowski RT, Bulcavage L, Grosvenor M, et al: Hydrazine sulfate in cancer patients with weight loss; A placebo-controlled clinical experience. Cancer 59: 406-410, 1987. (Pubitemid 17002415)
16. Chlebowski RT, Bulcavage L, Grosvenor M, et al: Hydrazine sulfate influence on nutritional status and survival in non-small-cell lung cancer. J Clin Oncol 8: 9-15, 1990. (Pubitemid 20032440)
17. Chlebowski RT, Heber D, Richardson B, et al: Influence of hydrazine sulfate on abnormal carbohydrate metabolism in cancer patients with weight loss. Cancer Res 44:857-861, 1984. (Pubitemid 14184631)
18. Tanaka Y, Eda H, Fujimoto K, et al: Anticachectic activity of 5'-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma. Cancer Res 50: 4528-4532, 1990. (Pubitemid 20230387)
19. Pannuti F, Di Marco AR, Martoni A, et al: Medroxyprogesterone acetate in the treatment of metastatic breast cancer; Seven years of experience. In: Iacobelli S, Di Marco A eds, Role of Medroxyprogesterone in Endocrine-related Tumors: Progress in Cancer Research and Therapy. Vol 15, Raven Press, New York, pp73-92, 1980.
20. Robustelli Della Cuna G, Bernardo-Strada MR, Ganzina F: High dose medroxyprogesterone acetate in metastatic breast cancer; A critical review. In: Cavalli F, McGuire WL, Pannuti F, Pellegrini A, Robustelli Della Cuna G eds, Proceedings of the International Symposium on Medroxyprogesterone Acetate Excerpta Medica, Amsterdam-Oxford-Princeton, pp290-305, 1982.
21. Johnson JR, Priestman TJ, Fotherby K, et al: An evaluation of high-dose medroxyprogesterone acetate therapy in women with advanced breast cancer. Br J Cancer 50:363-366, 1984.
22. Hsueh AJW, Peck JEJ, Clark JH: Progesterone antagonism of the oestrogen receptor and oestrogeninduced uterine growth. Nature 254:337-339, 1975.
23. Carlo FD, Conti G, Reboani C: Interference of gestagens and androgens with rat uterine oestrogen receptors. J Endocrinol 77:49-55, 1978. (Pubitemid 8301923)
24. Hellman L, Yoshida K, Zumoff B, et al: The effect of medroxyprogesterone acetate on the pituitary-adrenal axis. J Clin Endocrinol Metab 42:912-917, 1976.
25. Danguy A, Legros N, Devleeschouwer N, et al: Effects of medroxyprogesterone acetate (MPA) on growth of DMBA-induced rat mammary tumors; Histopathologic and endocrine studies. In: Iacobelli S, Di Marco A eds, Role of Medroxyprogesterone in Endocrinerelated Tumors; Progress in Cancer Research and Therapy. Vol 15, Raven Press, New York, pp21-28, 1980.
26. Blossey HC, Wander HE, Koebberling J, et al: Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate. Cancer 54:1208-1215, 1984. (Pubitemid 14037390)
27. Clarke CL, Sutherland RL: Progestin regulation of cellular proliferation. Endocr Rev 11:266-300, 1990.
28. Yamashita J, Hideshima T, Shirakusa T, et al: Medroxyprogesterone acetate treatment reduces serum interleukin-6 levels in patients with metastatic breast carcinoma. Cancer 78:2346-2352, 1996. (Pubitemid 26392834)
29. Van Meir EV, Sawamura Y, Diserens AC, et al: Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res 50:6683-6688, 1990. (Pubitemid 20348800)
30. Tabibzadeh SS, Poubouridis D, May LT, et al: Interleukin-6 immunoreactivity in human tumors. Am J Pathol 135: 427-433, 1989. (Pubitemid 19246200)
31. Watson JM, Sensintaffar JL, Berek JS, et al: Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res 50:6959-6965, 1990. (Pubitemid 20361098)
32. Siegall CB, Schwab G, Nordan RP: Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res 50:7784-7788, 1990.
33. Ishiko T, Mita S, Sakamoto K, et al: Fibroblast-tumor interaction changes constitutive expression of IL-6 and IL-8 in human carcinoma cells. Int J Oncol 6:639-645, 1995.
34. Adams EF, Rafferty B, White MC: Interleukin 6 is secreted by breast fibroblasts and stimulates 17β-oestradiol oxidoreductase activity of MCF-7 cells; Possible paracfine regulation of breast 17β-oestradiol levels. Int J Cancer 49:118-121, 1991.
35. Yamashita J, Hideshima T, Shirakusa T, et al: Primary tumor levels of interleukin 6 in relation to tumor burden in human breast cancer. Oncology Reports 1: 1185-1187, 1994. (Pubitemid 2159606)
36. Tchekmedyian NS, Tait N, Moody M, et al: Appetite stimulation with megestrol acetate in cachectic cancer patients. Semin Oncol 13:37-43, 1986. (Pubitemid 17020173)
37. Sedlacek SM: An overview of megestrol acetate for the treatment of advanced breast cancer. Semin Oncol 15:3-13, 1988.
38. Ross MB, Buzdar AU, Blumenschein GR: Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. Cancer 49:413-417, 1982. (Pubitemid 12213435)
39. Basedovsky H, Del Rey A: Immune-neuroendocrine circuits; Integrative role of cytokines. Front Neuroendocrinol 13:61-94, 1992.
40. Bateman A, Singh A, Kral T, et al: The immune-hypothalamic-pituitary- adrenal axis. Endocr Rev 10:92-112, 1989. (Pubitemid 19156369)
41. Hermus ARMM, Sweep CGJ: Cytokines and the hypothalamic-pituitary-adrenal axis. J Steroid Biochem Mol Biol 37:867-871, 1990.
42. Spangelo BL, Judo AM, Isakson PC, et al: Interleukin-6 stimulates anterior pituitary hormone release in vitro. Endocrinology 125:575-577, 1989. (Pubitemid 19182713)
43. Arzt E, Buric R, Stelzer G, et al: Interleukin involvement in anterior pituitary cell growth regulation; Effects of IL-2 and Ib6. Endocrinology 132: 459-467, 1993. (Pubitemid 23019537)
44. Bataille R, Jourdan M, Zhang XG, et al: Serum levels of intefleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 84:2008-2011, 1989. (Pubitemid 20016211)
45. Tamm I, Cardinale I, Krueger J, et al: Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells. J Exp Med 170:1649-1669, 1989. (Pubitemid 19284564)
46. Tamm I, Cardinale I, Murphy JS: Decreased adherence of interleukin 6-treated breast carcinoma cells can lead to separation from neighbors after mitosis. Proc NatI Acad Sci USA 88:4414-4418, 1991. (Pubitemid 21914550)
47. Yamashita J, Ogawa M, Egami H, et al: Abundant expression of immunoreactive endothelin-1 in mammary phyllodes tumor; Possible paracrine role of endothelin-1 in the growth of stromal cells in phyllodes tumor. Cancer Res 52:40464049, 1992.
48. Yamashita J, Ogawa M, Nomura K, et al: Intefleukin 6 stimulates the production of immunoreactive endothelin 1 in human breast cancer cells. Cancer Res 53:464-467, 1993. (Pubitemid 23059420)
49. Strassmann G, Fong M, Kenney J, et al: Evidence for the involvement of interleukin-6 in experimental cancer cachexia.J Clin Invest 89:1681-1684, 1992.
50. Ohe Y, Podack ER, Olsen KJ, et al: Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shorten survival in syngeneic mice. Br J Cancer 67:939-944, 1993. (Pubitemid 23147483)
51. Kuramoto M, Yamashita J, Ogawa M: Tissue-type plasminogen activator predicts endocrine responsiveness of human pancreatic carcinoma cells. Cancer 75:1263-1272, 1995.
52. Abe M, Yamashita J, Ogawa M: Medroxyprogesterone acetate inhibits human pancreatic carcinoma cell growth by inducing apoptosis in association with bcl-2 phosphorylation. Cancer (in press).